期刊文献+

高血压用药精细化及智能化管理系统开发 被引量:3

System Development for the Refined and Intelligent Management of Hypertension Medication
下载PDF
导出
摘要 目的:借助社区医院信息平台,开发高血压用药精细化及智能化管理系统。方法:根据《中国高血压防治指南》(基层版)高血压的药物治疗原则,和《临床用药须知》化学药和生物制品卷及药品说明书,建立高血压用药的知识库信息平台。结果与结论:通过该信息平台帮助医师注意用药安全、掌握用药的基本原则、确定正确的给药方案,发挥平台的药用前拦截、用药中警示、用药后提示等作用。 Objective: To develop a refined and intelligent management system for chronic diseases, such as high blood pressure, by dint of the community hospital information platform. Methods: The information platform of hypertension medication was established, According to the principle of high blood pressure medication outlined in Chinese Hypertension Prevention Guide(grassroots version) as well as the volume of chemical and biological drugs and the instruction of "Package Insert " taken from Clinical Pharmaceutical Guide. Results and Conclusion: Through this information platform, we can intercept misleading medication beforehand, warn physicians in treatment, remind after the treatment as well as the basic principles of medication after treatment, and finally give the correct medication plan.
出处 《中国药事》 CAS 2016年第10期1046-1050,共5页 Chinese Pharmaceutical Affairs
基金 上海交大闵行公共卫生管理研究中心科研项目(编号2014-JM-07)
关键词 高血压 降压药 知识库 精细化管理 临床用药指导 药学服务 医院药事管理 hypertension antihypertensive drugs knowledge base refined management clinical guidelines pharmaceutical care hospital pharmaceutical affairs management
  • 相关文献

参考文献11

二级参考文献81

  • 1史旭波.高血压复方制剂控制高血压更有效[J].中国医药导刊,2004,6(3):202-202. 被引量:3
  • 2孙宁玲.新型固定剂量复方抗高血压药物安博诺的临床应用[J].临床药物治疗杂志,2004,2(4):58-61. 被引量:2
  • 3中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5230
  • 4PhRMA. Record number of innovative new medicines for heart disease and stroke now in development [ EB/OL ]. (2009 -02 - 26) [ 2010 - 05 - 06 ]. http://www, phrma, org/news_room/ pressreleases/record_number of new_medicines for_heart_ disease_and_stroke_now_in_development.
  • 5PhRMA. New Medicines Database [ EB/OL]. [ 2009 -11 -05 ]. http://newmeds, phrma, org/results php? skin = phrma& drug = &indication = 38&company = &status =.
  • 6FDA. User Fee Billable Biologic Products and Potencies Approved Under Section 351 of the PHS Act [ EB/OL ]. (2010 - 04 - 06 ) [2010 -05 - 12 ]. http://www, takeda, com/press/article 36086. html.
  • 7Bayer Heahhcare Pharmaceuticals Inc. Effect of angeliq on blood pressure(BP) in postmenopausal hypertensive women[ EB/OL]. ( 2009 - 07 - 06) [ 2010 - 05 - 11 ]. http ://www. clinicaltrials- search, org/effect -of-angeliq-on-blood-pressure-bp-in-postmenopausal-hypertensive-women-nct00102141, html.
  • 8ROBINSON DE. King pharmaceuticals reports efficacy of ahace 20 mg and efficacy of a combination of ahace 20 mg and hydrochlorothiazide 25 mg for 24-hour blood pressure control [ EB/ OL].(2007-05 -19) [2010 -05 -11]. http://www, drugs. corn/ clinical_trials/king-pharmaceuticals-reports-efficacy-ahace- 20 mg-efficacy-combination-ahace-20 mg-903, html.
  • 9Takeda Pharmaceutical Company Limited. Takeda submits new drug application for azilsartan medoxomil in the U. S. , an investigational compound for the treatment of hypertension [ EB/OL]. (2010 -04 -27) [2010 -05 -11]. http://www, takeda, com/ press/ article_36086, html.
  • 10ClinicalTrials. gov. Efficacy and safety of azilsartan medoxomi| combined with chlorthalidone in subjects with moderate to severe hypertension[EB/OLl. (2010 -04 -09) [2010 -05 -03]. http://clinicaltrials, gov/ct2/show/ NCT008476267 term = Az- ilsartan + medoxomil&rank = 4.

共引文献921

同被引文献18

引证文献3

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部